PCRX (Pacira BioSciences) PEG Ratio : 3.56 (As of Mar. 02, 2025)

View and export this data going back to 2011. Start your Free Trial

What is Pacira BioSciences PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Pacira BioSciences's PE Ratio without NRI is 16.03. Pacira BioSciences's 5-Year EBITDA growth rate is 4.50%. Therefore, Pacira BioSciences's PEG Ratio for today is 3.56.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

The historical rank and industry rank for Pacira BioSciences's PEG Ratio or its related term are showing as below:

PCRX' s PEG Ratio Range Over the Past 10 Years
Min: 0.17 Med: 0.43 Max: 20.17
Current: 7.5

During the past 13 years, Pacira BioSciences's highest PEG Ratio was 20.17. The lowest was 0.17. And the median was 0.43.

PCRX's PEG Ratio is ranked worse than
89.26% of 363 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs PCRX: 7.50

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.

Pacira BioSciences PEG Ratio Historical Data

The historical data trend for Pacira BioSciences's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences PEG Ratio Chart

Pacira BioSciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

PEG Ratio

Get a 7-Day Free Trial

0.93

6.77

Pacira BioSciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
PEG Ratio	Get a 7-Day Free Trial															0.93	0.34	0.41	1.15	6.77

Competitive Comparison of Pacira BioSciences's PEG Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacira BioSciences's PEG Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's PEG Ratio falls into.

Pacira BioSciences PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Pacira BioSciences's PEG Ratio for today is calculated as

PEG Ratio	=	PE Ratio without NRI	/	5-Year EBITDA Growth Rate*
	=	16.033333333333	/	4.50
	=	3.56

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Pacira BioSciences (NAS:PCRX) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

Pacira BioSciences PEG Ratio Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacira BioSciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (NAS:PCRX) » Definitions » PEG Ratio

Comparable Companies

Traded in Other Exchanges

82P:Germany

Address

5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609

Website

https://www.pacira.com

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Executives

Jonathan Slonin	officer: Chief Clinical Officer	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Daryl Gaugler	officer: Chief Operating Officer	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Marcelo Bigal	director	C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Laura Brege	director	C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Michael J. Yang	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark Froimson	director	5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Kristen Marie Williams	officer: CAO and General Counsel	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Paul J Hastings	director	61 HARTFORD STREET, SAN FRANCISCO CA 94114
Lauren Bullaro Riker	officer: Executive Director, Accounting	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Gary W Pace	director	C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Alethia Young	director	C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Abraham Ceesay	director	C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830
Roy Winston	officer: Chief Clinical Officer	C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Mark A. Kronenfeld	director	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054
Reinhart Charles A. Iii	officer: Chief Financial Officer	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054